Apmis

doi: 10.1111/apm.13246pmid: N/A

Kresse, Jean‐Claude; Gregersen, Emil; Atay, Jasmine Cicek Leifing; Eijken, Marco; Nørregaard, Rikke

doi: 10.1111/apm.13352pmid: 37750005

Mesenchymal stromal/stem cell (MSC) therapy has been thoroughly tested in preclinical animal models and holds great promise for the treatment of kidney diseases. It is becoming increasingly evident that the efficacy of MSC therapy is dependent on several factors including dosage, the tissue source of MSCs, the route of delivery and timing of administration. In a time where MSC therapy is moving from preclinical research to clinically therapeutic use, the importance of choice of delivery method, modality, and administration route increases. In this review, we provide an overview of the different MSC delivery routes used in preclinical kidney disease models, highlight the recent advances in the field, and summarize studies comparing delivery routes of MSCs to the kidney.

Sipos, Ferenc; Műzes, Györgyi

doi: 10.1111/apm.13351pmid: 37729389

Good's syndrome, an infrequent adult‐onset immunodeficiency is characterized by the triad of thymoma, hypogammaglobulinemia, and increased susceptibility to recurrent infections. The clinical presentation is highly variable, with a spectrum ranging from recurrent bacterial and opportunistic infections to concomitant autoimmune diseases and, sometimes malignant pathologies. Due to heterogeneous clinical phenotypes and the lack of adequate diagnostic criteria, its recognition is often challenging, even delaying it by years. It is one of the most unusual, less studied form of the immune deficiency syndromes with a still unknown pathophysiology. It was initially considered a thymoma‐associated variant of primary antibody deficiencies with a reduced or absent number of mature B cells, but it later emerged that significant defects of T cell‐mediated immune functions are the underlying cause of opportunistic infections. On the basis of current evidence, Good's syndrome is evaluated as a distinct acquired form of combined immunodeficiency states and classified as a phenocopy of primary immunodeficiency diseases. Epigenetic and acquired genetic factors can play an ultimate role in its evolution.

Jacobsen, Mads‐Holger B.; Knudsen, Andreas D.; Benfield, Thomas; Ostrowski, Sisse R.; Afzal, Shoaib; Sørensen, Edith W.; Nielsen, Susanne D.; Gelpi, Marco

doi: 10.1111/apm.13354pmid: 37849049

In the present study, we aimed to investigate the association between soluble CD40 ligand (sCD40L, a marker of platelet activation), soluble thrombomodulin, and syndecan‐1 (both well‐described markers of endothelial dysfunction) and metabolic syndrome in a large cohort of well‐treated people with HIV (PWH) and to elucidate their association with HIV‐specific variables. We included 862 PWH with undetectable viral replication. Our hypotheses were tested using uni‐ and multivariable logistic regression models a priori adjusted for well‐known confounders. While no association of soluble thrombomodulin and syndecan‐1 with MetS was found, high levels of sCD40L (aOR 1.54 [1.07–2.22]) were associated with excess risk of MetS. Given the previously described association between sCD40L, vascular inflammation and endothelial damage, the results presented in our study may suggest a potential role for sCD40L in the well‐known association between cardiometabolic comorbidity and HIV infection.